Cell Therapy as Treatment for Cerebral Palsy

Neurogen Brain and Spine Institute

Status and phase: Withdrawn; Phase 1

Conditions: Cerebral Palsy

Treatments: Biological: Intrathecal autologous bone marrow mononuclear cell transplantation

Study type: Interventional

Funder types: Other

Identifiers

NCT02241395

NGBSI-09

Details and patient eligibility

About

The purpose of this study was to study the effect of autologous bone marrow mononuclear cells on common symptoms of cerebral palsy patients.

Sex: All

Ages: 6 months to 35 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• diagnosed cases of any type of Cerebral Palsy
• age above 6 months.

Exclusion criteria

• presence of acute infections such as Human immunodeficiency virus/Hepatitis B Virus/ Hepatitis C Virus
• malignancies
• bleeding tendencies
• pneumonia
• renal failure
• severe liver dysfunction
• severe anemia [Hemoglobin < 8]
• any bone marrow disorder
• space occupying lesion in brain
• other acute medical conditions such as respiratory infection and pyrexia.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

0 participants in 1 patient group

Stem Cell

Experimental group

Description:

Intrathecal autologous bone marrow mononuclear cell transplantation

Treatment:

Biological: Intrathecal autologous bone marrow mononuclear cell transplantation